Evolent Health, Inc (EVH) Lowered to "Sell" at Zacks Investment Research


A number of other analysts have also recently weighed in on the stock.

Needle moving action has been spotted in Evolent Health Inc (EVH) as shares are moving today on volatility 2.15% or 0.38 from the open. ValuEngine cut shares of Evolent Health from a "hold" rating to a "sell" rating in a report on Friday, July 28th.

Cowen and Company reaffirmed their outperform rating on shares of Evolent Health, Inc (NYSE:EVH) in a research report report published on Wednesday. "Ultimately, through all this investigation into the company's performance the analyst decides if their stock is a "buy", sell" or hold".

Zacks presents analysts with an ABR (Average Broker Rating), based on the sell-side recommendations. Evolent Health, Inc.is based in Arlington, Virginia. The company has market cap of $1.23 billion. The firm's 50 day moving average price is $24.94 and its 200 day moving average price is $22.68. After a recent check, the 14-day RSIfor Evolent Health Inc (EVH) is now at 19.36, the 7-day stands at 12.39, and the 3-day is sitting at 14.86.

Evolent Health (EVH) traded up 4.25% during mid-day trading on Tuesday, reaching $18.40. Moreover, Maltese Capital Management Llc has 0.42% invested in the company for 255,000 shares. The business had revenue of $107.30 million for the quarter, compared to analyst estimates of $104.45 million. The value of the company's investment in Evolent Health, Inc Class A went from $22,052,000 to $22,783,000 increasing 3.3% quarter over quarter.

More news: North Korea talk drags global stocks lower; gold, yen rise
More news: Wall Street reels under North Korea tensions, tepid retail earnings
More news: Tensions over North Korea weigh on stocks but boost gold

As of the latest earnings report the EPS was $-1.23 and is estimated to be $-0.41 for the current year with 65,822,000 shares now outstanding. During the same quarter in the prior year, the company earned ($0.20) EPS.

COPYRIGHT VIOLATION NOTICE: This news story was originally reported by Week Herald and is the property of of Week Herald. If you are viewing this article on another domain, it was copied illegally and reposted in violation of US and worldwide trademark & copyright laws. Evolent Health has a consensus rating of Buy and an average price target of $29.90.

In other news, CEO Frank J. Williams sold 16,300 shares of Evolent Health stock in a transaction dated Thursday, August 3rd. With 1.05M shares average volume, it will take short sellers 11 days to cover their EVH's short positions. Ameriprise Financial Inc. now owns 168,379 shares of the technology company's stock worth $4,269,000 after buying an additional 93,133 shares during the period. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Cheryl Scott sold 5,477 shares of Evolent Health stock in a transaction dated Friday, May 19th. "Similarly, the company's CEO, Valence Health WIGGINTON STEVE on 2017-08-01 Sell 6000 shares of the company at a price of $24.64". Teachers Advisors LLC now owns 25,119 shares of the technology company's stock valued at $372,000 after buying an additional 1,211 shares during the period.

Hedge funds have recently added to or reduced their stakes in the company. TIAA CREF Investment Management LLC increased its stake in shares of Evolent Health by 168.3% in the second quarter. American International Group Inc. now owns 9,403 shares of the technology company's stock valued at $210,000 after buying an additional 653 shares during the period. US Bancorp DE raised its position in shares of Evolent Health by 0.3% in the first quarter. JPMorgan Chase & Co. boosted its stake in Evolent Health by 123.0% in the first quarter. Handelsbanken Fonder AB acquired a new stake in Evolent Health during the first quarter valued at $1,784,000. FMR LLC boosted its stake in Evolent Health by 102.1% in the first quarter. American Century Companies Inc. now owns 162,116 shares of the technology company's stock valued at $3,615,000 after buying an additional 8,020 shares during the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank raised its position in shares of Evolent Health by 286.7% in the first quarter. Following the transaction, the president now owns 760,944 shares of the company's stock, valued at $19,023,600. Evolent Health had 20 analyst reports since August 7, 2015 according to SRatingsIntel. The Company supports health systems and physician organizations in their migration toward value-based care and population health management. (NASDAQ:TRUE) established that the company was able to keep return on investment at -14.05 in the trailing twelve month while Reuters data showed that industry's average stands at 17.89 and sector's optimum level is 12.55.